AI Article Synopsis
- The field of cancer diagnostics is evolving with the introduction of liquid biopsy, a less invasive method than traditional surgical biopsies, which uses blood or other bodily fluids to analyze tumor-derived materials.
- This review highlights recent studies that showcase the advancements in liquid biopsy technology and its potential applications in diagnosing and monitoring cancer.
- The authors also address the current challenges and future expectations for integrating liquid biopsy testing into clinical practice for improved cancer patient care.
Article Abstract
The field of cancer diagnostics has recently been impacted by new and exciting developments in the area of liquid biopsy. A liquid biopsy is a minimally invasive alternative to surgical biopsies of solid tissues, typically achieved through the withdrawal of a blood sample or other body fluids, allowing the interrogation of tumor-derived material including circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) fragments that are present at a given time point. In this short review, we discuss a few studies that summarize the state-of-the-art in the liquid biopsy field from a diagnostic perspective, and speculate on current challenges and expectations of implementing liquid biopsy testing for cancer diagnosis and monitoring in the clinical setting.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023445 | PMC |
| http://dx.doi.org/10.3390/diagnostics8020031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!